Josep Argerich

Josep Argerich

Auto-generated profile, based on publicly available information

Josep Argerich

Institute for Biocomputation and Physics of Complex Systems (BIFI) and Laboratorio de Microscopías Avanzadas (LMA), University of Zaragoza, 50018, Zaragoza, Spain

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 January 2020 in eLife
Verified
Journal Article
Open access
AEAlejandra Escudero-Lara
Alejandra Escudero-Lara
JAJosep Argerich
Josep Argerich
DCDavid Cabañero
David Cabañero
RMRafael Maldonado
Rafael Maldonado
Endometriosis is a chronic painful disease highly prevalent in women that is defined by growth of endometrial tissue outside the uterine cavity and lacks adequate treatment. Medical use of cannabis derivatives is a current hot topic and it is unknown whether phytocannabinoids may modify endometriosis symptoms and development. Here we evaluate the effects of repeated exposure to Δ9-tetrahydrocannabinol (THC) in a mouse model of surgically-induced endometriosis. In this model, female mice develop mechanical hypersensitivity in the caudal abdomen, mild anxiety-like behavior and substantial memory deficits associated with the presence of extrauterine endometrial cysts. Interestingly, daily treatments with THC (2 mg/kg) alleviate mechanical hypersensitivity and pain unpleasantness, modify uterine innervation and restore cognitive function without altering the anxiogenic phenotype. Strikingly, THC also inhibits the development of endometrial cysts. These data highlight the interest of scheduled clinical trials designed to investigate possible benefits of THC for women with endometriosis.

10 September 2024 in npj Parkinson's Disease
Verified
Journal Article
Open access
PDF file
JAJosep Argerich
Josep Argerich
LGLeonardo D. Garma
Leonardo D. Garma
MLMarc López-Cano
Marc López-Cano
PÁPaula Álvarez-Montoya
Paula Álvarez-Montoya
LGLaura Gómez-Acero
Laura Gómez-Acero
FRANCISCO CIRUELAFRANCISCO CIRUELA
FRANCISCO CIRUELA
The orphan G protein-coupled receptor 37 (GPR37), widely associated with Parkinson’s disease (PD), undergoes proteolytic processing under physiological conditions. The N-terminus domain is proteolyzed by a disintegrin and metalloproteinase 10 (ADAM-10), which generates various membrane receptor forms and ectodomain shedding (ecto-GPR37) in the extracellular environment. We investigated the processing and density of GPR37 in several neurodegenerative conditions, including Lewy body disease (LBD), multiple system atrophy (MSA), corticobasal degeneration (CBD), progressive supranuclear palsy (PSP), and Alzheimer’s disease (AD). The presence of ecto-GPR37 peptides in the cerebrospinal fluid (CSF) of PD, MSA, CBD and PSP patients was assessed through an in-house nanoluciferase-based immunoassay. This study identified increased receptor processing in early-stage LBD within the PFC and striatum, key brain areas in neurodegeneration. In MSA only the 52 kDa form of GPR37 appeared in the striatum. This form was also significantly elevated in the striatum of AD necropsies. On the contrary, GPR37 processing remained unchanged in the brains of CBD and PSP patients. Furthermore, while CSF ecto-GPR37 increased in PD patients, its levels remained unchanged in MSA, CBD, and PSP subjects. Importantly, patients with PD with rapid progression of the disease did not have elevated ecto-GPR37 in the CSF, while those with slow progression showed a significant increase, suggesting a possible prognostic use of ecto-GPR37 in PD. This research underscores the distinctive processing and density patterns of GPR37 in neurodegenerative diseases, providing crucial insights into its potential role as an indicator of PD progression rates.

8 August 2025 in Journal of Biological Chemistry
Verified
Journal Article
Open access
JAJosep Argerich
Josep Argerich
DMDaniel Muñoz-Reyes
Daniel Muñoz-Reyes
IVIris del Val-García
Iris del Val-García
JGJavier García-Nafría
Javier García-Nafría
G protein-coupled receptors (GPCRs) are a therapeutically privileged family of receptors, involved in a wide variety of pathophysiological conditions and the successful target for ∼34% of FDA-approved drugs. However, a significant percentage of GPCRs remain orphan, i.e. the endogenous ligands that modulate receptor function are unknown, and hence knowledge about their functional role and the generation of new therapeutics lag behind. During recent years, the use of cryo-electron microscopy has revolutionized GPCR structural biology including its application to orphan GPCRs, especially those displaying constitutive activity in cellular model systems. Such efforts have resulted in the description of new modes of in-built agonists that include the ECL2 and N-terminal regions, as well as identifying ubiquitous endogenous ligands readily bound to GPCRs. These results position structural determination as a new key component in GPCR deorphanization, shedding light on new signaling mechanisms, bringing questions about their functional regulation and opening new avenues for drug design.

30 October 2024 in Endocrinology
Verified
Journal Article
Closed access
PDF file
AAAlejandra Abeledo-Machado
Alejandra Abeledo-Machado
JAJosep Argerich
Josep Argerich
AYAgustín Yaneff
Agustín Yaneff
NVNOEMI VIDAL
NOEMI VIDAL
CGClaudia García-Roca
Claudia García-Roca
GDGraciela Díaz-Torga
Graciela Díaz-Torga
Prolactinomas, the most common pituitary-secreting adenomas, can be effectively treated with dopamine D2 receptor (D2R) agonists. However, a subset of them (∼20%) are resistant to dopamine (DA)-based therapies and require extirpation. The molecular mechanisms underlying their escape from dopaminergic regulation are not fully elucidated and may include alterations in D2R signaling. D2R can heteromerize with other G protein-coupled receptors, resulting in modulation of dopaminergic signaling. Since the bradykinin receptor type 2 (B2R) is overexpressed in prolactinomas, we interrogated whether this dopaminergic dysregulation observed in some prolactinomas may depend on a physical and functional interaction between D2R and B2R. The formation of B2R-D2R complexes in cultured cells transiently expressing both receptors was validated using NanoBiT technology. Interestingly, while D2R stimulation did not alter B2R-induced intracellular calcium mobilization, B2R stimulation abolished D2R signaling through modulation of cAMP. The existence of B2R-D2R complexes in pituitary adenomas (PitNet) biopsies was evaluated using an ALPHALisa approach. Importantly, B2R-D2R complexes were detected in human prolactinomas and nonfunctioning pituitary adenomas (NFPA), but not in mixed (prolactin + growth hormone) secreting adenomas. These results suggest that overexpression of B2R in resistant prolactinomas may promote the formation of B2R-D2R complexes, with B2R precluding D2R signaling, thus generating resistance to D2R agonists.

27 March 2020 in Molecules
Verified
Journal Article
Open access
PDF file
VFVíctor Fernández-Dueñas
Víctor Fernández-Dueñas
MQMingcheng Qian
Mingcheng Qian
JAJosep Argerich
Josep Argerich
CACarolina Amaral
Carolina Amaral
MRMartijn D.P. Risseeuw
Martijn D.P. Risseeuw
FRANCISCO CIRUELAFRANCISCO CIRUELA
FRANCISCO CIRUELA
In recent years, new drug discovery approaches based on novel pharmacological concepts have emerged. Allosteric modulators, for example, target receptors at sites other than the orthosteric binding sites and can modulate agonist-mediated activation. Interestingly, allosteric regulation may allow a fine-tuned regulation of unbalanced neurotransmitter’ systems, thus providing safe and effective treatments for a number of central nervous system diseases. The metabotropic glutamate type 5 receptor (mGlu5R) has been shown to possess a druggable allosteric binding domain. Accordingly, novel allosteric ligands are being explored in order to finely regulate glutamate neurotransmission, especially in the brain. However, before testing the activity of these new ligands in the clinic or even in animal disease models, it is common to characterize their ability to bind mGlu5Rs in vitro. Here, we have developed a new series of fluorescent ligands that, when used in a new NanoBRET-based binding assay, will facilitate screening for novel mGlu5R allosteric modulators.

5 November 2023 in IBRO Neuroscience Reports
Verified
Journal Article
Open access
MLMarc López-Cano
Marc López-Cano
JAJosep Argerich
Josep Argerich
MVMarta Valle-León
Marta Valle-León
AFAlejandro Fernández-Solanas
Alejandro Fernández-Solanas
VFVíctor Fernández-Dueñas
Víctor Fernández-Dueñas